Silver Book Fact

Treatment with bisphosphonates are highly cost-effective in women over the age of 70 with osteoporosis and a previous fracture.

Fleurence, Rachael L., Cynthia P. Iglesias, and Jeanene M. Johnson. The Cost Effectiveness of Bisphosphonates for the Prevention and Treatment of Osteoporosis: A structured review of the literature. PharmacoEcon. 2007; 25(11): 913-33. http://www.ncbi.nlm.nih.gov/pubmed/17960951

Reference

Title
The Cost Effectiveness of Bisphosphonates for the Prevention and Treatment of Osteoporosis: A structured review of the literature
Publication
PharmacoEcon
Publication Date
2007
Authors
Fleurence, Rachael L., Cynthia P. Iglesias, and Jeanene M. Johnson
Volume & Issue
Volume 25, Issue 11
Pages
913-33
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Risedronate, a bisphosphonate, has been shown to reduce vertebral fractures by around 41%, hip fractures by 30%, and non-vertebral fractures by 39%.  
  • Ibandronate, a bisphosphonate, taken daily has been shown to reduce the risk of new vertebral fractures by around 62%.  
  • Treatment with zoledronic acid over a 3-year period reduced risk of vertebral fracture by around 70% and risk of hip fracture by 41%, and increased bone mineral density (BMD) by…  
  • Teriparatide, or human recombinant PTH, has been shown to increase vertebral bone mineral density (BMD) by 9% to 13%.  
  • Teriparatide, or human recombinant PTH, has been shown to decrease vertebral fractures by 65% to 69%, and non-vertebral fragility fractures by around 53%.